Russian oil spill may slide Dr Reddy's, Glenmark in Q3
This article was originally published in Scrip
Executive Summary
The devaluation of the rouble is expected to hurt the fiscal Q3 earnings of a clutch of leading Indian firms, with the negative effect potentially spilling over into the fourth quarter as well, some analysts say.
You may also be interested in...
Turbulence Ahead For Indian Firms Caught In Russia-Ukraine Conflict
Leading Indian firms with operations in the war zone stare at uncertainties and disruptions as sanctions by the US and Western allies threaten to choke the Russian economy.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.